EcoDrugPlus

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSPNAG00000008167
Gene Symbol: RAF1
3 Cross references
152 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSPNAG00000023657
Gene Symbol: ROCK1
3 Cross references
215 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSPNAG00000013168
Gene Symbol: ROCK2
3 Cross references
225 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSPNAG00000007840
Gene Symbol: SRC
4 Cross references
190 Possible Orthologues:

Tek Receptor Tyrosine Kinase

Ensembl ID : ENSPNAG00000026138
Gene Symbol: TEK
3 Cross references
163 Possible Orthologues:

Tgf-Beta Receptor Type-1-Like

Ensembl ID : ENSPNAG00000019914
Gene Symbol: LOC108441712
3 Cross references
205 Possible Orthologues:

Tgf-Beta Receptor Type-1-Like

Ensembl ID : ENSPNAG00000019941
Gene Symbol: LOC108441711
3 Cross references
205 Possible Orthologues:

Ttk Protein Kinase

Ensembl ID : ENSPNAG00000006249
Gene Symbol: TTK
3 Cross references
204 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSPNAG00000016623
Gene Symbol: UGCG
3 Cross references
211 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSPNAG00000017548
Gene Symbol: WEE1
3 Cross references
205 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSPNAG00000014028
Gene Symbol: WEE1
4 Cross references
141 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSPNAG00000000667
Gene Symbol: YES1
4 Cross references
149 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).